Delving into the Latest Updates on Propiverine Hydrochloride with Synapse

A total of 40 volunteers women with a diagnosis of interstitial cystitis. Their ages ranged from 25 to 40 years old; their body mass index was > 30 kg/m2 and were randomly assigned to a group (A) received interferential current at the lower abdomen, and also received traditional medicine or group (B) received traditional medicine for 8 successive weeks. Both of the groups received the treatment program for 8 successive weeks. Assessment of pain perception and disability level for all patients in both groups (A&B) were done through Visual analogue scale, O'Leary-Sant Symptom Index or Interstitial Cystitis Index (ICSI) and blood cortisol concentration were done before and after the treatment program.

Start Date01 Jan 2019

Sponsor / Collaborator

Cairo University

NCT03602508 / CompletedNot Applicable

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.
This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

Start Date20 Jul 2018

Sponsor / Collaborator

Astellas Pharma Singapore Pte Ltd.

NCT02294396 / CompletedPhase 4

Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron

The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.

Start Date28 Oct 2014

Sponsor / Collaborator

Astellas Pharma, Inc.

100 Clinical Results associated with Propiverine Hydrochloride

Login to view more data

100 Translational Medicine associated with Propiverine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Propiverine Hydrochloride

Login to view more data

1,849

Literatures (Medical) associated with Propiverine Hydrochloride

01 Aug 2024·Journal of Dairy Science

Effect of 200 μg of gonadorelin hydrochloride at the first GnRH of a CO-Synch program on ovulation rate and pregnancies per artificial insemination in Holstein heifers

Article

Author: Melo, D B ; Menezes, M C G ; Castro, T ; Lima, F S ; Salman, S ; Coelho, W M ; Cotterman, R F ; Monteiro, H F ; Marques, T C ; Conley, A J ; Macedo, I M

The initial ovulatory response during synchronization programs is often low in dairy heifers, largely due to follicular dynamics and hormonal dynamics. Specifically, the progesterone (P4) concentration at the time of the first GnRH treatment in a breeding program can influence the LH response, often resulting in a suboptimal ovulatory response. The objective of this study was to determine the effect of the highest label dose 200 μg (100 μg vs. 200 μg) of GnRH (50 μg of gonadorelin hydrochloride per mL; Factrel, Zoetis Inc. Madison, NJ) at the first GnRH of a 6-d CO-Synch plus P4 device program on ovulatory response and pregnancy per AI (P/AI) in first service in Holstein heifers. A total of 1,308 Holstein heifers were randomly allocated at the beginning of a 6-d CO-Synch program at day 0 to receive either i.m. treatment of 100 μg (2CC, n = 655) or 200 μg (4CC, n = 653) of GnRH. Also, at d 0, heifers received an intravaginal insert with 1.38 g of P4 (Eazi-Breed CIDR Cattle Insert, Zoetis Inc.). On day 6, the insert was removed, and i.m. treatment of 25 mg of PGF_2α (12.5 mg of dinoprost tromethamine/mL; Lutalyse HighCon Injection, Zoetis Inc.) was administered. On d 7, a second i.m. treatment of 25 mg of PGF_2α was given, followed on d 9 by concurrent i.m. treatment of 100 μg of GnRH, and timed AI. A subset of 396 heifers had their ovaries scanned to evaluate ovulatory response, and blood samples were collected to measure the serum concentration of P4 at d 0 and d 6 of the study. The P4 concentrations at d 0 were categorized as low (≤3 ng/mL) or high (>3 ng/mL). The ovulatory response was greater for heifers receiving 4CC than 2CC at d 0 (54.7% vs. 42.8%). The ovulatory response was greater for low P4 than high P4 at d 0 (54.3% vs. 37.8%). However, we did not observe an interaction between treatment and P4 concentrations (low P4 2CC = 48.6% vs. high P4 2CC = 30.0%; low P4 4CC = 60.0% vs. high P4 4CC = 45.5%). The receiver operating characteristic curve analysis indicated that P4 concentrations at d 0 treatment could predict the ovulatory response, although the area under the curve was only 0.6. As expected, heifers that ovulated had increased P/AI (no = 55.6% vs. yes = 67.7%); however, we found no effect of treatment on P/AI (2CC = 63.3% vs. 4CC = 59.6%), and no interactions between treatment and ovulation and treatment and P4 (high vs. low) for pregnancy outcomes. In summary, P4 concentration and increasing the dose of GnRH at d 0 positively affected ovulatory response in Holstein heifers. However, there was no interaction between treatment and P4 on ovulation and no subsequent impact of GnRH dose on P/AI.

01 Jul 2024·Journal of Biological Chemistry

Decline in corepressor CNOT1 in the pregnant myometrium near term impairs progesterone receptor function and increases contractile gene expression

Article

Author: Montalbano, Alina P ; Colon-Caraballo, Mariano ; Mahendroo, Mala ; Mendelson, Carole R ; Kwak, Youn-Tae ; Kelleher, Andrew M ; Kraus, W Lee

Progesterone (P₄), acting via its nuclear receptor (PR), is critical for pregnancy maintenance by suppressing proinflammatory and contraction-associated protein (CAP)/contractile genes in the myometrium. P₄/PR partially exerts these effects by tethering to NF-κB bound to their promot-ers, thereby decreasing NF-κB transcriptional activity. However, the underlying mechanisms whereby P₄/PR interaction blocks proinflammatory and CAP gene expression are not fully understood. Herein, we characterized CCR-NOT transcription complex subunit 1 (CNOT1) as a corepressor that also interacts within the same chromatin complex as PR-B. In mouse myome-trium increased expression of CAP genes Oxtr and Cx43 at term coincided with a marked decline in expression and binding of CNOT1 to NF-κB-response elements within the Oxtr and Cx43 promoters. Increased CAP gene expression was accompanied by a pronounced decrease in enrichment of repressive histone marks and increase in enrichment of active histone marks to this genomic region. These changes in histone modification were associated with changes in expression of corresponding histone modifying enzymes. Myometrial tissues from P₄-treated 18.5 dpc pregnant mice manifested increased Cnot1 expression at 18.5 dpc, compared to vehicle-treated controls. P₄ treatment of PR-expressing hTERT-HM cells enhanced CNOT1 expression and its recruitment to PR bound NF-κB-response elements within the CX43 and OXTR promoters. Furthermore, knockdown of CNOT1 significantly increased expression of contractile genes. These novel findings suggest that decreased expression and DNA-binding of the P₄/PR-regulated transcriptional corepressor CNOT1 near term and associated changes in histone modifications at the OXTR and CX43 promoters contribute to the induction of myometrial contractility leading to parturition.

01 Jul 2024·Domestic Animal Endocrinology

Role of steroid hormones in the maintenance of focal adhesions in bovine oviductal epithelial cells

Article

Author: Vella, Milda Alejandra ; De Boeck, Maximiliano ; Valdecantos, Pablo Alberto ; García, Daniela Celeste ; Roldán-Olarte, Mariela

The oviduct, the organ of the female reproductive system where fertilization and early embryonic development occur, provides an optimal environment for the final maturation of oocytes, storage, and sperm capacitation and transport of gametes and embryos. During the estrous cycle, the oviduct is affected by ovarian sex hormones, resulting in changes aimed at maintaining an appropriate microenvironment. Normal cell migration is tightly regulated, its role being essential for the development and maintenance of organ and tissue functions as well as for regeneration following injury. Due to their involvement in focal contact formations, focal adhesion kinase (PTK2) and paxillin (PXN) are key proteins in the study of cell migration and adhesion. The objective of this work was to compare the expression of PTK2 and PXN in oviductal cells along the estrous cycle and to determine if their expression is regulated by the presence of 17-β estradiol (E₂) and/or progesterone (P₄). No transcripts of PTK2 or of PXN were detected in cells corresponding to the luteal phase. Additionally, hormonal stimulation experiments on bovine oviductal cell cultures (BOECs) were carried out, where P₄ inhibited the expression of both genes. Migration assays demonstrated that P₄ reduced BOECs migration capacity. P₄ treatment also reduced cell adhesion, while E₂ increased the number of adhered cells. In conclusion, the presence of E₂ and P₄ regulates the expression of genes involved in the formation of focal contacts and modifies the migration and adhesion of BOECs. Understanding the effect of steroid hormones on BOECs is critical to grasp the impact of steroid control on oviductal function and its contribution to establishing successful pregnancies.

100 Deals associated with Propiverine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01007	Propiverine Hydrochloride	G04BD06	DB12278

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neurogenic detrusor overactivity	CA	Duchesnay, Inc.	05 Jan 2017
Urinary Bladder, Overactive	CA	Duchesnay, Inc.	05 Jan 2017
Urinary Incontinence	JP	Taiho Pharmaceutical Co., Ltd.	02 Apr 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urinary Incontinence, Urge	Phase 1	CN	APOGEPHA Arzneimittel GmbH	01 Jan 2010
Urinary Bladder, Neurogenic	Phase 1	RO	APOGEPHA Arzneimittel GmbH	01 Dec 2004
Urinary Bladder, Neurogenic	Phase 1	DE	APOGEPHA Arzneimittel GmbH	01 Dec 2004
Urinary Bladder, Neurogenic	Phase 1	AT	APOGEPHA Arzneimittel GmbH	01 Dec 2004
syndrome; salt-losing, adrenogenital syndrome	Phase 1	-	APOGEPHA Arzneimittel GmbH	01 Oct 2004
Neurogenic detrusor overactivity	Phase 1	-	APOGEPHA Arzneimittel GmbH	01 Jun 2004
Urinary Bladder, Overactive	Phase 1	-	APOGEPHA Arzneimittel GmbH	01 Jun 2004
Urinary Incontinence	Phase 1	-	APOGEPHA Arzneimittel GmbH	01 Jun 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02294396 (CTgov)	Phase 4	Urinary Bladder, Overactive	649	Mirabegron tablet+Solifenacin tablet (Mirabegron + Solifenacin)	ndqynhgeor(odrcgcjrpa) = ndflckqzzd iwgqtduwmw (urnwbqlynd, vrxkpziujm - blbscwapdd) View more	-	24 Dec 2018
				Mirabegron tablet+Propiverine tablet (Mirabegron + Propiverine)	ndqynhgeor(odrcgcjrpa) = jwtcvimdaw iwgqtduwmw (urnwbqlynd, lxitjjjend - akxslcssjh) View more
NCT01512004 (Pubmed \| BJU Int) Manual	Phase 3	Urinary Bladder, Overactive	324	propiverine	boerajkqjk(gdhubotxrd) = bmkwxwjhln sxlsdelrcl (vqtzjvbrry, 4.1) View more	Non-inferior	01 Jan 2017
				tolterodine	boerajkqjk(gdhubotxrd) = vhgpmizwfo sxlsdelrcl (vqtzjvbrry, 5.1) View more
NCT00903045 (Pubmed \| BJU Int)	Phase 4	Urinary Bladder, Overactive	264	Propiverine 20 mg	snsxrnirkt(adcobewbli) = sceuhdysam rutzeijxwp (wgiyzdrxwx )	Positive	01 Jun 2010
				Placebo	snsxrnirkt(adcobewbli) = xgvqpvnpkj rutzeijxwp (wgiyzdrxwx )
NCT00795925 (Pubmed \| Clin Pharmacokinet)	Phase 2	Urinary Bladder, Overactive	25	Propiverine 5 mg	(osiwsswizj) = Most of the adverse events that were probably or possibly drug related were reported for patients in the high-dose group (>0.45 mg/kg) muswobqmnm (qwucriwmmk )	-	01 May 2010
				Propiverine 10 mg
NCT00603343 (Pubmed \| J Urol)	Phase 3	Urinary Incontinence \| Urinary Bladder, Overactive	171	Propiverine	(hnzmqzthcj) = yxftnchpow djjafovntk (thalfglvns ) View more	Positive	01 Mar 2009
				Placebo	(hnzmqzthcj) = irwppxibzm djjafovntk (thalfglvns ) View more